Codiak Biosciences Inc. (CDAK) PT Raised to 'Street High' $31 at Wedbush Following Data

Go back to Codiak Biosciences Inc. (CDAK) PT Raised to 'Street High' $31 at Wedbush Following Data

Codiak BioSciences (CDAK) Announces Positive Initial Phase 1 Results for exoIL-12 Demonstrating Tolerability & Absence of Systemic IL-12 Exposure in Healthy Volunteers

December 30, 2020 7:02 AM EST

Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the primary objectives were met in the initial part of its Phase 1 trial, which evaluated a single ascending dose of exoIL-12 in healthy volunteers. In this randomized, placebo controlled, double-blind study, exoIL-12 demonstrated a favorable safety and tolerability profile, with no local or systemic treatment-related adverse events and no detectable systemic exposure of IL-12.

This is an important milestone, as these results show that... More